Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Accumulated Depreciation (2023 - 2025)

Cardiff Oncology's Accumulated Depreciation history spans 6 years, with the latest figure at $4.5 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation rose 7.98% year-over-year to $4.5 million; the TTM value through Dec 2025 reached $4.5 million, up 7.98%, while the annual FY2025 figure was $4.5 million, 7.98% up from the prior year.
  • Accumulated Depreciation for Q4 2025 was $4.5 million at Cardiff Oncology, up from $4.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $4.5 million in Q4 2025 and bottomed at $3.8 million in Q4 2023.
  • The 3-year median for Accumulated Depreciation is $4.1 million (2024), against an average of $4.2 million.
  • The largest annual shift saw Accumulated Depreciation increased 10.26% in 2024 before it rose 7.98% in 2025.
  • A 3-year view of Accumulated Depreciation shows it stood at $3.8 million in 2023, then grew by 10.26% to $4.1 million in 2024, then grew by 7.98% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Accumulated Depreciation are $4.5 million (Q4 2025), $4.4 million (Q2 2025), and $4.1 million (Q4 2024).